Ildong Holdings Co Ltd - Asset Resilience Ratio
Ildong Holdings Co Ltd (000230) has an Asset Resilience Ratio of 3.06% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000230 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Ildong Holdings Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 000230 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Ildong Holdings Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Ildong Holdings Co Ltd (000230) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩24.23 Billion | 3.06% |
| Total Liquid Assets | ₩24.23 Billion | 3.06% |
Asset Resilience Insights
- Limited Liquidity: Ildong Holdings Co Ltd maintains only 3.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ildong Holdings Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ildong Holdings Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Ildong Holdings Co Ltd (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Ildong Holdings Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.15% | ₩1.20 Billion ≈ $814.19K |
₩802.86 Billion ≈ $544.09 Million |
-1.64pp |
| 2024-12-31 | 1.79% | ₩15.28 Billion ≈ $10.35 Million |
₩854.70 Billion ≈ $579.22 Million |
-1.78pp |
| 2023-12-31 | 3.57% | ₩31.29 Billion ≈ $21.21 Million |
₩877.00 Billion ≈ $594.33 Million |
-0.77pp |
| 2022-12-31 | 4.34% | ₩37.42 Billion ≈ $25.36 Million |
₩862.55 Billion ≈ $584.54 Million |
+1.49pp |
| 2021-12-31 | 2.84% | ₩26.19 Billion ≈ $17.75 Million |
₩920.76 Billion ≈ $623.99 Million |
+2.21pp |
| 2020-12-31 | 0.64% | ₩5.09 Billion ≈ $3.45 Million |
₩799.40 Billion ≈ $541.74 Million |
+0.23pp |
| 2019-12-31 | 0.41% | ₩3.30 Billion ≈ $2.23 Million |
₩805.63 Billion ≈ $545.96 Million |
-1.28pp |
| 2018-12-31 | 1.69% | ₩4.49 Billion ≈ $3.04 Million |
₩265.47 Billion ≈ $179.90 Million |
+0.75pp |
| 2017-12-31 | 0.94% | ₩2.59 Billion ≈ $1.76 Million |
₩274.84 Billion ≈ $186.25 Million |
-1.55pp |
| 2016-12-31 | 2.49% | ₩5.09 Billion ≈ $3.45 Million |
₩204.09 Billion ≈ $138.31 Million |
+1.93pp |
| 2015-12-31 | 0.56% | ₩3.98 Billion ≈ $2.69 Million |
₩705.64 Billion ≈ $478.20 Million |
+0.16pp |
| 2014-12-31 | 0.40% | ₩2.48 Billion ≈ $1.68 Million |
₩620.35 Billion ≈ $420.40 Million |
-0.03pp |
| 2013-12-31 | 0.43% | ₩2.68 Billion ≈ $1.82 Million |
₩628.21 Billion ≈ $425.73 Million |
-0.19pp |
| 2012-12-31 | 0.62% | ₩3.35 Billion ≈ $2.27 Million |
₩541.71 Billion ≈ $367.11 Million |
-0.43pp |
| 2011-12-31 | 1.05% | ₩5.35 Billion ≈ $3.63 Million |
₩511.65 Billion ≈ $346.74 Million |
-2.64pp |
| 2010-12-31 | 3.68% | ₩19.57 Billion ≈ $13.27 Million |
₩531.23 Billion ≈ $360.01 Million |
+2.68pp |
| 2009-12-31 | 1.00% | ₩4.96 Billion ≈ $3.36 Million |
₩495.53 Billion ≈ $335.82 Million |
-0.34pp |
| 2008-12-31 | 1.34% | ₩5.43 Billion ≈ $3.68 Million |
₩404.79 Billion ≈ $274.32 Million |
+0.48pp |
| 2007-12-31 | 0.86% | ₩2.90 Billion ≈ $1.96 Million |
₩336.03 Billion ≈ $227.73 Million |
-0.07pp |
| 2006-12-31 | 0.93% | ₩2.64 Billion ≈ $1.79 Million |
₩283.77 Billion ≈ $192.31 Million |
+0.57pp |
| 2005-12-31 | 0.36% | ₩941.26 Million ≈ $637.88K |
₩258.07 Billion ≈ $174.89 Million |
-0.09pp |
| 2004-12-31 | 0.45% | ₩1.05 Billion ≈ $709.94K |
₩232.19 Billion ≈ $157.35 Million |
-0.30pp |
| 2003-12-31 | 0.75% | ₩1.65 Billion ≈ $1.12 Million |
₩218.82 Billion ≈ $148.29 Million |
+0.20pp |
| 2002-12-31 | 0.56% | ₩1.09 Billion ≈ $741.62K |
₩195.90 Billion ≈ $132.76 Million |
-0.14pp |
| 2001-12-31 | 0.70% | ₩1.27 Billion ≈ $863.51K |
₩183.11 Billion ≈ $124.09 Million |
-0.21pp |
| 2000-12-31 | 0.91% | ₩1.70 Billion ≈ $1.15 Million |
₩187.75 Billion ≈ $127.23 Million |
+0.78pp |
| 1999-12-31 | 0.12% | ₩234.02 Million ≈ $158.59K |
₩188.81 Billion ≈ $127.96 Million |
-- |
About Ildong Holdings Co Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the… Read more